Katrine Søholt Juul-Andersen serves as Associate Director, Legal Counsel for Corporate Strategy at Genmab, where she leverages her extensive expertise in corporate law and legal compliance to drive strategic initiatives within the pharmaceutical industry. With a robust background in negotiation and legal writing, Katrine plays...
Katrine Søholt Juul-Andersen serves as Associate Director, Legal Counsel for Corporate Strategy at Genmab, where she leverages her extensive expertise in corporate law and legal compliance to drive strategic initiatives within the pharmaceutical industry. With a robust background in negotiation and legal writing, Katrine plays a pivotal role in supporting Business Development, Corporate Development, and Alliance Management. Her responsibilities encompass a diverse range of activities, including the structuring and negotiation of collaborations, partnerships, and licensing agreements, as well as overseeing asset purchases and commercialization strategies.
Katrine's academic credentials, including a Master in Business Administration and Commercial Law from Copenhagen Business School, complement her practical experience, allowing her to navigate the complexities of pharmaceutical law with agility. She is adept at managing compliance issues, ensuring adherence to Good Distribution Practices (GDP), and providing legal advice that aligns with both corporate objectives and regulatory requirements. Her involvement in equity and venture capital investments, along with mergers and acquisitions (M&A), underscores her strategic insight and ability to foster growth opportunities for Genmab.
In her role, Katrine not only focuses on legal compliance but also actively contributes to the development of innovative solutions that enhance the company’s competitive edge in the market. Her commitment to excellence and her comprehensive understanding of the pharmaceutical landscape position her as a key asset to Genmab, driving forward the company's mission to improve the lives of patients through groundbreaking therapies.
